A New and Surprising Approach to Cancer Treatment: SENOTHERAPY

With each passing day, we encounter a new treatment approach in cancer. In May 2020, Nature published a study in which senotherapy, by "targeting dormant cells", prevented the proliferation of liver cancer cells in mouse models. This is the first study in hepatocellular carcinoma (liver cancer) to apply senotherapy.
Senotherapy targets dormant (non-dividing) cells using small-molecule inhibitors. Senotherapeutic properties are used in anti-aging approaches. The study investigated the applicability of senotherapy in liver cancers. For this purpose, the FB1 (fructose 1,6-bisphosphatase 1) gene in liver cells was analyzed. Loss of the FBP1 enzyme in human liver cells significantly increases tumor growth. Previous research has shown that FBP1 levels are low in stage 1 /early-stage) tumors and fall further as the disease progresses.
According to the Research Results
- The FB1 enzyme was found to be present at low levels in hepatocellular carcinoma (HCC), the most common type of liver cancer.
- Liver cancer was observed to progress rapidly in mice in which FBP1 enzyme activity was inhibited through genetic engineering. Liver tumor growth was also observed after loss of FB1 enzyme activity, independently of underlying factors such as obesity, alcoholism, and hepatitis.
- The researchers succeeded in halting tumor progression by targeting these aged cells with senolytic drugs such as Navitoclax (a drug undergoing clinical trials for the treatment of hematologic malignancies), to prevent tumor progression caused by liver-cell-specific loss of FBP1.
What Does This Study Mean for Us?
- This is the first genetic study to show that the BP1 enzyme is an important metabolic tumor suppressor in the liver. It was also discovered that abnormalities in the FB1 gene in liver cells affect the tumor microenvironment and thereby promote tumor growth.
- Senotherapy has been shown to have potential benefits against liver cancer.
- Senotherapy targets "non-cancerous and dormant" cells in the tumor microenvironment. These dormant cells have been found to promote the development of cancer.
- Cells in the tumor microenvironment are also an important factor reducing the effectiveness of immunotherapies. Combining senotherapy and immunotherapy may offer an effective cancer treatment.
It must be emphasized that this study was carried out in a laboratory setting. These findings need to be confirmed through further clinical studies.
Related Topics:
- Aging cancer cells continue to survive by eating one another
Sources
FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome.
Nature Cell Biology, 4 May 2020.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.